Press release
Pulmonary Arterial Hypertension Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Pulmonary Arterial Hypertension Pipeline. Dive into DelveInsight's comprehensive report today! @ Pulmonary Arterial Hypertension Pipeline Outlook [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Pulmonary Arterial Hypertension Pipeline Report
* On September 3, 2025, the International University of Health and Welfare initiated a study to evaluate the efficacy of satralizumab in patients with pulmonary arterial hypertension (PAH) characterized by an immune-responsive phenotype, defined as serum interleukin-6 (IL-6) levels greater than or equal to 2.73 pg/mL, who have demonstrated an inadequate response to existing therapies.
* DelveInsight's Pulmonary Arterial Hypertension Pipeline report depicts a robust space with 55+ active players working to develop 55+ pipeline therapies for Pulmonary Arterial Hypertension treatment.
* The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others.
* Promising Pulmonary Arterial Hypertension Pipeline Therapies such as TPN171H, Tadalafil, Bosentan, Satralizumab (Genetical Recombination), PF-07868489, Sotatercept, Macitentan, Treprostinil Palmitil and others.
Get insights into Pulmonary Arterial Hypertension Clinical Trials, emerging therapies, and leading companies with DelveInsight @ Pulmonary Arterial Hypertension Treatment Drugs [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pulmonary Arterial Hypertension Emerging Drugs Profile
* Sotatercept: Acceleron Pharma
Sotatercept is a first-in-class therapeutic fusion protein comprised of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). It provides balance of the growth-promoting activin growth differentiation factor pathway, and the growth-inhibiting BMP pathway by serving as a ligand trap for the TGF- superfamily. The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is in Phase III clinical trial for the treatment of PAH.
* LIQ861: Liquidia Technologies
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company's novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient, palm-sized dry powder inhaler. Liquidia resubmits New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH). The Pulmonary Arterial Hypertension Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension Treatment.
* Pulmonary Arterial Hypertension Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Pulmonary Arterial Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Arterial Hypertension market
Explore groundbreaking therapies and clinical trials in the Pulmonary Arterial Hypertension Pipeline. Access DelveInsight's detailed report now! @ New Pulmonary Arterial Hypertension Drugs [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pulmonary Arterial Hypertension Companies
Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others.
Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
* Molecule Type
Pulmonary Arterial Hypertension Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Learn about new Pulmonary Arterial Hypertension drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pulmonary Arterial Hypertension Market Drivers and Barriers [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Pulmonary Arterial Hypertension Pipeline Report
* Coverage- Global
* Pulmonary Arterial Hypertension Companies- Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others.
* Pulmonary Arterial Hypertension Pipeline Therapies- TPN171H, Tadalafil, Bosentan, Satralizumab (Genetical Recombination), PF-07868489, Sotatercept, Macitentan, Treprostinil Palmitil and others.
* Pulmonary Arterial Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Pulmonary Arterial Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download DelveInsight's in-depth Pulmonary Arterial Hypertension Pipeline report today! @ Pulmonary Arterial Hypertension Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Pulmonary Arterial Hypertension: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Pulmonary Arterial Hypertension - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Sotatercept: Acceleron Pharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* GB-002: Gossamer Bio
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Apabetalone: Resverlogix
* Drug profiles in the detailed report.....
* Preclinical/Discovery Stage Products
* R107: Radikal Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Pulmonary Arterial Hypertension Key Companies
* Pulmonary Arterial Hypertension Key Products
* Pulmonary Arterial Hypertension- Unmet Needs
* Pulmonary Arterial Hypertension- Market Drivers and Barriers
* Pulmonary Arterial Hypertension- Future Perspectives and Conclusion
* Pulmonary Arterial Hypertension Analyst Views
* 26. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pulmonary-arterial-hypertension-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Arterial Hypertension Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4170774 • Views: …
More Releases from ABNewswire
The Original Water Lantern Festival Makes UK Debut with Events in Manchester, Bi …
Voted USA Today's #1 Cultural Festival, the original floating lantern experience is now lighting up UK waters for the first time
Sept. 4, 2025 - United Kingdom - Water Lantern Festival [https://www.waterlanternfestival.com/uk?utm_source=PR&utm_medium=Traditional%2BPR&utm_campaign=PR], the original and most celebrated floating lantern event in the world, is making its highly anticipated UK debut this September in Manchester, Birmingham, London and Edinburgh, with more dates to be announced.
Unlike recent imitators, Water Lantern Festival is the…
Dual Citizenship for Entrepreneurs: Leveraging Opportunities in USA & Mexico.
In this blog, we'll explore the major benefits of dual citizenship for entrepreneurs and business owners, from property ownership to business financing, and share insights from clients who have successfully navigated these opportunities.
In today's global economy, operating seamlessly across borders offers a significant advantage for entrepreneurs and business owners. This key tool facilitates cross-border access to dual citizenship, especially between countries like the U.S. and Mexico. For Mexican-Americans or those…
AI Will Kill PowerPoint? Consultants Don't Think So.
In professional services, predictability beats gimmicks. Firms still value tools that provide control, consistency, and uniform results over flashy but unreliable alternatives.
For the last two years, the consulting world has been split into two camps. On one side, the believers: those convinced that AI-generated slide tools will automate away the tedious parts of PowerPoint, making consultants faster or even unnecessary. On the other side, the skeptics: those who have actually…
Veteran PE Aleksandr Treyger Named PDH-Pro's 2025 "Engineering Educator of the Y …
Veteran engineer Aleksandr Treyger, P.E., has been named the 2025 "Engineering Educator of the Year" by PDH-Pro. The inaugural award honors Treyger for his exceptional ability to translate complex theory into practical, real-world applications for licensed professional engineers. He was selected based on outstanding student satisfaction scores and his significant impact on the profession.
WELLESLEY, Mass. - Sept. 4, 2025 - PDH-Pro, a leading provider of online continuing education for professional…
More Releases for Pulmonary
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028.
The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
